SLFN11 expression level is a promising predictive biomarker: it not only predicts the benefit of platinum-based chemotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC), but also shows the potential to predict the sensitivity of specific subpopulations (such as RB1 WT AR+) to new targeted therapies such as B7H3-PBD-ADC, providing an important basis for personalized treatment strategies for advanced prostate cancer. This evidence concerns the gene SLFN11 and prostate cancer.